Antiplatelet agents may offer clinical benefits in ischemic stroke not only by preventing thrombosis but also by modulating inflammation via platelet-leukocyte interactions.
Answers are grounded in this paper and cite their sources.
May extend antiplatelet benefits in stroke beyond antithrombosis; leaves open confirmation in prospective trials before practice change.
Stroke is a common and often fatal event, and, in survivors, it is accompanied by a high risk of recurrence. Ischemic stroke is associated with abnormal platelet activity and thrombus formation. In addition to their roles in the development of acute thrombi, platelets serve as a bridge for leukocytes within the vasculature. Myeloid leukocytes are critical mediators of atherosclerosis and atherothrombosis. Interactions between platelets and leukocytes foster an inflammatory and thrombotic milieu that influences lesion progression, facilitates plaque rupture, and triggers thrombus formation and embolization. Accordingly, antiplatelet agents, including aspirin, dipyridamole, and clopidogrel, are recommended therapies for most patients with a history of stroke. In addition to mitigating thrombosis, antiplatelet drugs have direct and indirect effects on inflammation, which may translate to enhanced clinical efficacy.
No takes yet. Share an insight, caveat, or question.
Franks et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: